Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12067MR)

This product GTTS-WQ12067MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12067MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4379MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ4811MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ9906MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ68MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ6729MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ15101MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ13145MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ1057MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW